Detalles de la búsqueda
1.
Association between quality of life and treatment response in children with attention Deficit Hyperactivity Disorder and their parents.
J Ment Health Policy Econ
; 17(3): 119-29, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25543115
2.
Public preferences for the allocation of societal resources over different healthcare purposes.
Soc Sci Med
; 341: 116536, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38176245
3.
Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial.
BMC Psychiatry
; 13: 36, 2013 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-23347693
4.
Rethinking the eidos, genos, and diaphora of the health utility concept: a psychological perspective.
Front Psychol
; 14: 1139931, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37404589
5.
Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision-making?
Cancer Med
; 12(5): 6105-6116, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36373590
6.
Differences between expert reported and patient reported burden of disease rankings.
Sci Rep
; 12(1): 895, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042859
7.
Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
CNS Drugs
; 22(2): 157-70, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18193926
8.
Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
Eur J Cancer
; 41(14): 2102-11, 2005 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16140526
9.
Evaluating adherence to the Dutch guideline for diagnosis, treatment and follow-up of laryngeal carcinomas.
Radiother Oncol
; 74(3): 337-44, 2005 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15763316
10.
Cost determinants in aggressive non-Hodgkin's lymphoma.
Haematologica
; 90(5): 661-71, 2005 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15921381
11.
Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
Haematologica
; 90(10): 1422-32, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16219580
12.
Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands.
Springerplus
; 4: 224, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26155437
13.
Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
Pharmacoeconomics
; 33(5): 489-509, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25715975
14.
Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate.
Int J Radiat Oncol Biol Phys
; 59(2): 488-94, 2004 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15145167
15.
Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Haematologica
; 89(9): 1109-17, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15377472
16.
A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma.
Hematol J
; 4(6): 399-409, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-14671611
17.
Unit costs of inpatient hospital days.
Pharmacoeconomics
; 21(4): 263-71, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12600221
18.
Chemotherapy and high-dose-rate brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high technology--is it worth the cost?
Brachytherapy
; 1(1): 11-20, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-15062182
19.
Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD.
Eur J Health Econ
; 15(9): 967-77, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24233919
20.
Cost utility of telaprevir-PR (peginterferon-ribavirin) versus boceprevir-PR and versus PR alone in chronic hepatitis C in The Netherlands.
Appl Health Econ Health Policy
; 12(6): 647-59, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25103219